<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-36238" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Methylprednisolone</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ocejo</surname>
            <given-names>Antonio</given-names>
          </name>
          <aff>Universidad de Sonora</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Correa</surname>
            <given-names>Ricardo</given-names>
          </name>
          <aff>University of Arizona</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Antonio Ocejo declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ricardo Correa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>8</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-36238.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Methylprednisolone is an FDA-approved medication used for managing and treating various conditions, including allergic reactions, arthritis, asthma exacerbations, long-term asthma maintenance, and acute exacerbations of multiple sclerosis. As a systemic corticosteroid, methylprednisolone exhibits anti-inflammatory and immunosuppressive properties, effectively treating endocrine, inflammatory, immunologic, hematologic, and respiratory disorders. This activity focuses on the medication's indications, mechanisms, and contraindications, emphasizing the importance of understanding its role in different organ systems. Additionally, methylprednisolone's&#x000a0;adverse event profiles, pharmacokinetics, clinical toxicology, monitoring, and drug interactions will also be discussed.</p>
        <p>Understanding the intricate pharmacology of this synthetic corticosteroid helps healthcare professionals tailor treatment plans to meet individual patient needs. This initiative enhances&#x000a0;clinician proficiency regarding&#x000a0;methylprednisolone therapy to ensure patient-centered care. The goal is to minimize adverse effects while maximizing therapeutic efficacy, thus improving patient outcomes and elevating standards of care. By optimizing methylprednisolone therapy, healthcare providers can deliver personalized and safe management for conditions requiring this medication, promoting optimal patient outcomes and enhancing the overall quality of care.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of methylprednisolone.</p></list-item><list-item><p>Assess&#x000a0;the potential adverse drug reactions of methylprednisolone.</p></list-item><list-item><p>Select the appropriate monitoring parameters for patients on methylprednisolone.</p></list-item><list-item><p>Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from methylprednisolone therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=36238&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=36238">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-36238.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Methylprednisolone is a systemic synthetic corticosteroid that exerts a wide range of physiologic effects similar to naturally occurring glucocorticoids. Methylprednisolone is&#x000a0;typically prescribed due to its anti-inflammatory and immunosuppressive activity in the human body.&#x000a0;The FDA-approved indications and off-label uses for methylprednisolone&#x000a0;therapy&#x000a0;are listed&#x000a0;below.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>The following indications for methylprednisolone administration approved by the U.S. Food and Drug Administration are categorized below by organ system.</p>
        <p>
<bold>Dermatology:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Atopic dermatitis</p>
          </list-item>
          <list-item>
            <p>Contact dermatitis</p>
          </list-item>
          <list-item>
            <p>Pemphigus vulgaris</p>
          </list-item>
          <list-item>
            <p>Pemphigus foliaceous</p>
          </list-item>
          <list-item>
            <p>Bullous pemphigus</p>
          </list-item>
          <list-item>
            <p>Erythema multiforme</p>
          </list-item>
          <list-item>
            <p>Stevens-Johnson syndrome</p>
          </list-item>
          <list-item>
            <p>Toxic epidermal necrolysis&#x000a0;<xref ref-type="bibr" rid="article-36238.r1">[1]</xref><xref ref-type="bibr" rid="article-36238.r2">[2]</xref><xref ref-type="bibr" rid="article-36238.r3">[3]</xref><xref ref-type="bibr" rid="article-36238.r4">[4]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Endocrinology:</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Congenital adrenal hyperplasia associated with cancer</p>
          </list-item>
          <list-item>
            <p>Hypercalcemia associated with cancer</p>
          </list-item>
          <list-item>
            <p>Primary or secondary adrenocortical insufficiency (as a second-line treatment in conjunction with mineralocorticoids)</p>
          </list-item>
        </list>
        <p>
<bold>Gastroenterology:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Inflammatory bowel disease (acute exacerbations)&#x000a0;<xref ref-type="bibr" rid="article-36238.r5">[5]</xref><xref ref-type="bibr" rid="article-36238.r6">[6]</xref><xref ref-type="bibr" rid="article-36238.r7">[7]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Hematology:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Autoimmune hemolytic anemia</p>
          </list-item>
          <list-item>
            <p>Congenital (erythroid) aplastic anemia</p>
          </list-item>
          <list-item>
            <p>Immune thrombocytopenia&#x000a0;<xref ref-type="bibr" rid="article-36238.r8">[8]</xref><xref ref-type="bibr" rid="article-36238.r9">[9]</xref><xref ref-type="bibr" rid="article-36238.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Neurology:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Multiple sclerosis (acute exacerbations)&#x000a0;<xref ref-type="bibr" rid="article-36238.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Ophthalmology:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Uveitis</p>
          </list-item>
          <list-item>
            <p>Scleritis</p>
          </list-item>
          <list-item>
            <p>Chorioretinitis</p>
          </list-item>
          <list-item>
            <p>Iritis and iridocyclitis</p>
          </list-item>
          <list-item>
            <p>Keratitis</p>
          </list-item>
          <list-item>
            <p>Optic neuritis</p>
          </list-item>
          <list-item>
            <p>Retinal vasculitis</p>
          </list-item>
          <list-item>
            <p>Allergic conjunctivitis</p>
          </list-item>
        </list>
        <p>
<bold>Nephrology:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Nephrotic syndrome (idiopathic or secondary to lupus nephritis)&#x000a0;<xref ref-type="bibr" rid="article-36238.r12">[12]</xref><xref ref-type="bibr" rid="article-36238.r13">[13]</xref><xref ref-type="bibr" rid="article-36238.r14">[14]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Pulmonology:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Aspiration pneumonitis</p>
          </list-item>
          <list-item>
            <p>Asthma</p>
          </list-item>
          <list-item>
            <p>Chronic beryllium disease</p>
          </list-item>
          <list-item>
            <p>Disseminated pulmonary tuberculosis (as an adjunct to antituberculous chemotherapy)</p>
          </list-item>
          <list-item>
            <p>Eosinophilic pneumonia</p>
          </list-item>
          <list-item>
            <p>Symptomatic sarcoidosis<bold>&#x000a0;</bold><xref ref-type="bibr" rid="article-36238.r15">[15]</xref><xref ref-type="bibr" rid="article-36238.r16">[16]</xref><xref ref-type="bibr" rid="article-36238.r17">[17]</xref><xref ref-type="bibr" rid="article-36238.r18">[18]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Rheumatology:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute rheumatic carditis</p>
          </list-item>
          <list-item>
            <p>Acute gout</p>
          </list-item>
          <list-item>
            <p>Ankylosing spondylitis</p>
          </list-item>
          <list-item>
            <p>Dermatomyositis and polymyositis</p>
          </list-item>
          <list-item>
            <p>Psoriatic arthritis</p>
          </list-item>
          <list-item>
            <p>Rheumatoid arthritis (including juvenile type)</p>
          </list-item>
          <list-item>
            <p>Systemic lupus erythematosus&#x000a0;<xref ref-type="bibr" rid="article-36238.r19">[19]</xref><xref ref-type="bibr" rid="article-36238.r20">[20]</xref><xref ref-type="bibr" rid="article-36238.r21">[21]</xref><xref ref-type="bibr" rid="article-36238.r22">[22]</xref><xref ref-type="bibr" rid="article-36238.r23">[23]</xref><xref ref-type="bibr" rid="article-36238.r24">[24]</xref><xref ref-type="bibr" rid="article-36238.r25">[25]</xref></p>
          </list-item>
        </list>
        <p>The&#x000a0;FDA-approved indications and methods for the administration of methylprednisolone acetate formulation specifically are listed below.<xref ref-type="bibr" rid="article-36238.r26">[26]</xref><xref ref-type="bibr" rid="article-36238.r27">[27]</xref><xref ref-type="bibr" rid="article-36238.r28">[28]</xref><xref ref-type="bibr" rid="article-36238.r29">[29]</xref><xref ref-type="bibr" rid="article-36238.r30">[30]</xref><xref ref-type="bibr" rid="article-36238.r31">[31]</xref></p>
        <p>
<bold>Intra-articular and soft tissue administration:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Acute gouty arthritis</p>
          </list-item>
          <list-item>
            <p>Acute and subacute bursitis</p>
          </list-item>
          <list-item>
            <p>Acute tenosynovitis</p>
          </list-item>
          <list-item>
            <p>Epicondylitis</p>
          </list-item>
          <list-item>
            <p>Synovitis of osteoarthritis</p>
          </list-item>
        </list>
        <p>
<bold>Intralesional administration: </bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Alopecia areata</p>
          </list-item>
          <list-item>
            <p>Discoid lupus erythematosus</p>
          </list-item>
          <list-item>
            <p>Keloid disease</p>
          </list-item>
          <list-item>
            <p>Lichen planus</p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Methylprednisolone may be administered for&#x000a0;the following conditions or scenarios. The U.S. Food and Drug Administration has not approved these indications.</p>
        <list list-type="bullet">
          <list-item>
            <p>As adjunct therapy for patients with acute spinal cord injury.<xref ref-type="bibr" rid="article-36238.r32">[32]</xref> The&#x000a0;administration of methylprednisolone within 8 hours following a spinal cord injury requires careful individual consideration due to potential complications.<xref ref-type="bibr" rid="article-36238.r33">[33]</xref></p>
          </list-item>
          <list-item>
            <p>Myasthenia gravis&#x000a0;<xref ref-type="bibr" rid="article-36238.r34">[34]</xref></p>
          </list-item>
          <list-item>
            <p>Severe urticaria&#x000a0;<xref ref-type="bibr" rid="article-36238.r35">[35]</xref></p>
          </list-item>
          <list-item>
            <p>Sj&#x000f6;gren's syndrome&#x000a0;<xref ref-type="bibr" rid="article-36238.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p>Severe/refractory nausea and vomiting during pregnancy&#x000a0;<xref ref-type="bibr" rid="article-36238.r37">[37]</xref></p>
          </list-item>
          <list-item>
            <p>COVID-19 requiring oxygen or ventilatory support&#x000a0;<xref ref-type="bibr" rid="article-36238.r38">[38]</xref></p>
          </list-item>
          <list-item>
            <p>Amiodarone-induced thyrotoxicosis (drug-resistant)&#x000a0;<xref ref-type="bibr" rid="article-36238.r39">[39]</xref></p>
          </list-item>
          <list-item>
            <p>Moderate to severe acute distress respiratory syndrome (ARDS)</p>
          </list-item>
          <list-item>
            <p>Severe alcoholic hepatitis</p>
          </list-item>
          <list-item>
            <p>As a preventive agent in bronchiolitis obliterans syndrome</p>
          </list-item>
          <list-item>
            <p>Hormonal resuscitation in cadaveric organ recovery</p>
          </list-item>
          <list-item>
            <p>Acute cellular&#x000a0;or antibody-mediated rejection in cardiac transplant</p>
          </list-item>
          <list-item>
            <p>As adjunct therapy for patients with acute exacerbation of chronic obstructive pulmonary disease (COPD)</p>
          </list-item>
          <list-item>
            <p>As adjunct treatment of <italic toggle="yes">Pneumocystis</italic> pneumonia in patients with HIV</p>
          </list-item>
          <list-item>
            <p>As a palliative&#x000a0;option for patients with castration-resistant metastatic prostate cancer</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-36238.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Methylprednisolone and its derivatives, methylprednisolone acetate succinate and methylprednisolone sodium, are intermediate-acting synthetic glucocorticoids. They are typically prescribed as anti-inflammatory or immunosuppressive agents. As an anti-inflammatory, methylprednisolone is 5 times&#x000a0;as potent&#x000a0;as&#x000a0;hydrocortisone (cortisol) while demonstrating minimal mineralocorticoid activity.<xref ref-type="bibr" rid="article-36238.r40">[40]</xref>&#x000a0;Methylprednisolone diffuses&#x000a0;passively across the cellular membrane and binds to the intracellular glucocorticoid receptor. This complex translocates into the nucleus to interact with specific DNA sequences and enhance or suppress the transcription of particular genes. The methylprednisolone-glucocorticoid receptor complex blocks the promoter sites of proinflammatory genes,&#x000a0;promotes the expression of anti-inflammatory gene products,&#x000a0;and inhibits the synthesis of inflammatory cytokines; these actions are accomplished primarily by blocking the function of transcription factors, such as nuclear factor-kappa-B (NF-kB).<xref ref-type="bibr" rid="article-36238.r41">[41]</xref><xref ref-type="bibr" rid="article-36238.r42">[42]</xref><xref ref-type="bibr" rid="article-36238.r43">[43]</xref>&#x000a0;</p>
        <p>As a corticosteroid, methylprednisolone also suppresses the synthesis of cyclooxygenase (COX)-2, an enzyme that produces prostaglandins in damaged tissue&#x000a0;and contributes to the inflammation cascade.<xref ref-type="bibr" rid="article-36238.r44">[44]</xref>&#x000a0;Through these actions, methylprednisolone can&#x000a0;reduce or prevent inflammation by reversing capillary permeability, suppressing the migration of fibroblasts and polymorphonuclear leukocytes, controlling the rate of protein synthesis, and stabilizing lysosomes at the cellular level.</p>
        <p>Methylprednisolone inhibits cell-mediated immunologic functions, especially those dependent on lymphocytes. Glucocorticoid administration results in neutrophilic leukocytosis,&#x000a0;reduced monocyte elevations, dramatic reductions in circulating eosinophils, and&#x000a0;milder reductions in lymphocytes. Methylprednisolone and other glucocorticoids reduce leukocytes' ability to adhere to vascular endothelium and exit the circulation. Glucocorticoids impair various T-cell functions; moderate and high doses induce T-cell apoptosis while preserving B-cell functions, including antibody production.<xref ref-type="bibr" rid="article-36238.r45">[45]</xref>&#x000a0;Tissue-specific responses to steroids can occur due to specific protein regulators in each tissue controlling the interaction between the hormone-receptor complex and particular DNA response elements. This activity leads to a wide array of gene expression and physiological responses by corticosteroids.</p>
        <p>Some of the most critical effects of methylprednisolone and&#x000a0;other corticosteroids result from homeostatic responses by insulin and glucagon. Glucocorticoids stimulate gluconeogenesis, which elevates blood glucose levels, increases muscle protein and bone catabolism, and stimulates insulin secretion.&#x000a0;Glucocorticoids&#x000a0;stimulate&#x000a0;lipolysis and lipogenesis, causing&#x000a0;a net increase of fat deposition in some body areas (ie, face, shoulders, and back).<xref ref-type="bibr" rid="article-36238.r46">[46]</xref>&#x000a0;Glucocorticoids also cause wasting of lymphoid and connective tissue, fat, and skin at high doses. Catabolic effects on the bone can lead to osteoporosis in adults and growth inhibition in children.</p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Depending on the administration route and dose, a 2-compartment (for high IV doses) or 1-compartment model (for lower IV and oral doses) is appropriate&#x000a0;for&#x000a0;describing methylprednisolone's&#x000a0;pharmacokinetics. Methylprednisolone exhibits rapid and linear absorption, with peak concentrations achieved 48 minutes after administration. The onset of action of intravenous methylprednisolone succinate&#x000a0;occurs within 1 hour. For intra-articular methylprednisone acetate, the onset of action occurs at 1 week and lasts&#x000a0;1 to 5 weeks.&#x000a0;Methylprednisolone has an oral bioavailability of approximately 88%.</p>
        <p><bold>Distribution:</bold>&#x000a0;Methylprednisolone succinate has a volume of distribution (V<sub>d</sub>) of 24 &#x000b1; 6 L and a steady-state volume of distribution (V<sub>ss</sub>) of 27 &#x000b1; 8.2 L.&#x000a0;This drug primarily binds to albumin in plasma.</p>
        <p><bold>Metabolism:</bold>&#x000a0; Methylprednisolone undergoes hepatic metabolism to produce metabolites such as 20-carboxymethylprednisolone and 6&#x003b2;-hydroxy-20&#x003b1;-hydroxymethylprednisolone.</p>
        <p><bold>Elimination:</bold>&#x000a0;Methylprednisolone is&#x000a0;primarily excreted&#x000a0;in urine, following a bi-exponential pattern.<xref ref-type="bibr" rid="article-36238.r47">[47]</xref>&#x000a0;The half-life elimination of intravenous methylprednisolone is 0.25 hours, with an oral half-life of 2-5 hours.<xref ref-type="bibr" rid="article-36238.r48">[48]</xref><xref ref-type="bibr" rid="article-36238.r49">[49]</xref></p>
      </sec>
      <sec id="article-36238.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Methylprednisolone is available in tablet formulations of 2 mg, 4 mg, 8 mg, 16 mg, and 32 mg, injectable suspension formulations at concentrations of 20 mg/mL, 40 mg/mL, and 80 mg/mL, and as a powder for injection in doses of 40 mg, 125 mg, 500 mg, 1000 mg, and 2000 mg.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Methylprednisolone may be administered orally with food or milk to&#x000a0;reduce gastrointestinal adverse effects.&#x000a0;Methylprednisolone&#x000a0;may also be administered intramuscularly or intravenously. When administered intramuscularly (methylprednisolone acetate or succinate), it should not be injected into the deltoid muscle, which may cause&#x000a0;subcutaneous atrophy. Injections into the dermis or areas with evidence of acute local infection should be avoided. Intravenous administration (methylprednisolone succinate) is rate-dependent upon the dose and severity of the condition. Methylprednisolone is most commonly administered over 15 to 60 minutes with intermittent infusion. Large doses should be administered over a minimum of 30 minutes. Hypotension, arrhythmia, and sudden death have been reported when methylprednisolone doses of 250 mg or greater are administered in less than 30 minutes.<xref ref-type="bibr" rid="article-36238.r50">[50]</xref></p>
        <p><bold>COVID-19:</bold> For most patients with COVID-19 requiring supplemental oxygen, the National Institutes of Health (NIH) advises dexamethasone plus remdesivir; if dexamethasone is unavailable, clinicians can consider methylprednisolone, prednisone or hydrocortisone.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/hospitalized-adults--therapeutic-management/">[78]</ext-link></p>
        <p>A recent cohort study investigated the impact of intravenous (IV) methylprednisolone pulse therapy on in-hospital mortality risk in patients with acute COVID-19. Among patients receiving invasive mechanical ventilation, IV methylprednisolone pulse therapy at doses of 500 to 1000 mg daily&#x000a0;reduced the risk of in-hospital mortality compared to those not receiving steroid pulse therapy or intermediate steroid doses.<xref ref-type="bibr" rid="article-36238.r51">[51]</xref></p>
        <p><bold>Anaphylaxis:</bold>&#x000a0;The American Academy of Allergy, Asthma, and Immunology guidelines recommend that 1.0 to 2.0 mg/kg per dose of methylprednisolone be administered for adjunct treatment of anaphylaxis. Antihistamines and corticosteroids are adjunctive therapies for patients with anaphylaxis; epinephrine remains the primary treatment.<xref ref-type="bibr" rid="article-36238.r52">[52]</xref></p>
        <p><bold>Ulcerative colitis:</bold> The American College of Gastroenterology (ACG) recommends methylprednisolone 60 mg daily for remission in patients with severe ulcerative colitis.<xref ref-type="bibr" rid="article-36238.r53">[53]</xref></p>
        <p><bold>Lupus nephritis:</bold> According to the KDGIO 2024 guidelines, methylprednisolone pulses may be followed by a regimen of glucocorticoids during the initial treatment of active lupus nephritis upon satisfactory improvement in renal and extrarenal disease manifestations. Initial treatment typically involves IV methylprednisolone at a dose of 0.25 to 0.5 g/day for up to 3 days.<xref ref-type="bibr" rid="article-36238.r54">[54]</xref>&#x000a0;The study investigated the effects of high-dose methylprednisolone (above 100 mg) during cardiac arrest, revealing improved rates of sustained return of spontaneous circulation (ROSC) and overall survival at hospital discharge.<xref ref-type="bibr" rid="article-36238.r55">[55]</xref></p>
        <p><bold>Asthma exacerbation:</bold>&#x000a0;According to the Global Initiative for Asthma (GINA) guidelines, methylprednisolone should be administered to patients 5 years or younger at 1 mg/kg, followed by oral steroids based upon clinical response.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf">[79]</ext-link></p>
        <p><bold>Juvenile idiopathic arthritis:</bold>&#x000a0;Methylprednisolone can be used to treat juvenile idiopathic arthritis. However, intra-articular glucocorticoids such as triamcinolone are recommended as part of the initial therapy for active oligoarthritis.<xref ref-type="bibr" rid="article-36238.r56">[56]</xref></p>
        <p><bold>Steroid-resistant nephrotic syndrome:</bold>&#x000a0;According to the International Pediatric Nephrology Association, pulse therapy with&#x000a0;intravenous&#x000a0;methylprednisolone (500 mg/m<sup>2</sup>&#x000a0;or 15 mg/kg)&#x000a0;may&#x000a0;be considered&#x000a0;for patients with&#x000a0;steroid-resistant nephrotic syndrome.<xref ref-type="bibr" rid="article-36238.r57">[57]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment: </bold>No dosage adjustments are provided in the product labeling. Caution is advised.</p>
        <p><bold>Renal impairment: </bold>No dose adjustment is required; caution is advised as high corticosteroid doses&#x000a0;are associated with scleroderma renal crisis.<xref ref-type="bibr" rid="article-36238.r58">[58]</xref></p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>The American College of Obstetricians and Gynecologists (ACOG) recommends steroids such as prednisone or methylprednisolone during pregnancy due to their conversion to less active forms facilitated by 11&#x003b2;-hydroxysteroid dehydrogenase in the human placenta.<xref ref-type="bibr" rid="article-36238.r59">[59]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>Methylprednisolone levels in breast milk are very low, with no reported adverse effects on breastfed infants even after intravenous doses of 1 g. These infants&#x000a0;are exposed to doses lower than their daily cortisol production, well below therapeutic neonatal doses. There is no accumulation of methylprednisolone in breast milk with consecutive daily doses. To minimize infant exposure, breastfeeding should be avoided during and for 2 hours after a 1 g intravenous dose. Smaller oral doses and local injections (eg, for tendinitis) do not require special precautions. However, systemic or joint injections, especially with medium to large corticosteroid doses, may temporarily reduce lactation.<xref ref-type="bibr" rid="article-36238.r60">[60]</xref></p>
        <p><bold>Pediatric patients:</bold>&#x000a0;Weight-based dosing is preferred for pediatric patients.</p>
        <p><bold>Older patients:</bold>&#x000a0;According to the American College of Rheumatology (ACR), intravenous glucocorticoid&#x000a0;pulse doses are recommended&#x000a0;for patients with&#x000a0;giant cell arteritis (GCA), with methylprednisolone at a dosage range of 500 to 1000 mg per day for 5 days in adults.<xref ref-type="bibr" rid="article-36238.r61">[61]</xref>&#x000a0;Doses typically start at the lower end of the range due to the higher prevalence of reduced renal or cardiac function, concurrent diseases, and other medications.</p>
      </sec>
      <sec id="article-36238.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The significant adverse effects of glucocorticoids stem from their hormonal actions, which can result in iatrogenic Cushing syndrome. Facial rounding, puffiness, fat deposition, and plethora&#x000a0;(moon facies) are usually apparent. Fat redistributes from the extremities to the trunk, the back of the neck, and the supraclavicular fossae. Fine hair grows more quickly on the face, thighs, and trunk. Steroid-induced punctate acne may appear, and insomnia and increased appetite may be observed. With concurrent use of methylprednisolone, protein catabolism continues, diverting amino acids to glucose production, thus increasing the need for insulin and resulting in weight gain. Myopathy and muscle wasting can occur, as well as skin thinning, with striae and bruising. Hyperglycemia and osteoporosis can develop, as well as diabetes and aseptic necrosis of the hip.<xref ref-type="bibr" rid="article-36238.r62">[62]</xref>&#x000a0;</p>
        <p>The adverse&#x000a0;reactions associated&#x000a0;with methylprednisolone and other corticosteroids are classified based on the different organ systems affected below.</p>
        <p>
<bold>Dermatology:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Skin thinning</p>
          </list-item>
          <list-item>
            <p>Ecchymoses</p>
          </list-item>
          <list-item>
            <p>Cushingoid features</p>
          </list-item>
          <list-item>
            <p>Weight gain<xref ref-type="bibr" rid="article-36238.r63">[63]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Ophthalmology:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Cataracts</p>
          </list-item>
          <list-item>
            <p>Increased intraocular pressure</p>
          </list-item>
          <list-item>
            <p>Exophthalmos</p>
          </list-item>
        </list>
        <p>
<bold>Cardiovascular:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Fluid retention</p>
          </list-item>
          <list-item>
            <p>Hypertension</p>
          </list-item>
          <list-item>
            <p>Premature atherosclerotic disease</p>
          </list-item>
          <list-item>
            <p>Arrhythmias</p>
          </list-item>
          <list-item>
            <p>Hyperlipidemia</p>
          </list-item>
        </list>
        <p>
<bold>Gastrointestinal:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Gastritis</p>
          </list-item>
          <list-item>
            <p>Ulcer formation</p>
          </list-item>
          <list-item>
            <p>Gastrointestinal bleeding&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Musculoskeletal:</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Osteoporosis</p>
          </list-item>
          <list-item>
            <p>Osteonecrosis</p>
          </list-item>
          <list-item>
            <p>Myopathy</p>
          </list-item>
        </list>
        <p><bold>Neuropsychiatric:</bold>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Mood disorders</p>
          </list-item>
          <list-item>
            <p>Psychosis</p>
          </list-item>
          <list-item>
            <p>Memory impairment</p>
          </list-item>
        </list>
        <p>
<bold>Metabolic and endocrine:</bold>
<xref ref-type="bibr" rid="article-36238.r64">[64]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hyperglycemia</p>
          </list-item>
          <list-item>
            <p>Hypothalamic-pituitary-adrenal axis suppression<bold>&#x000a0;</bold><xref ref-type="bibr" rid="article-36238.r64">[64]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Immune:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Increased susceptibility to infections</p>
          </list-item>
        </list>
        <p>
<bold>Hematologic:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Leukocytosis</p>
          </list-item>
          <list-item>
            <p>Neutrophilia&#x000a0;(due to peripheral demargination)&#x000a0;<xref ref-type="bibr" rid="article-36238.r65">[65]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p><bold>Chimeric antigen receptor T-cell therapy (CAR T-cell therapy):</bold>&#x000a0;There is concern regarding the use of prophylactic corticosteroids due to the potential risk of diminishing CAR T-cell activity in the context of CAR T-cell therapy. Despite these concerns, existing evidence suggests that administering corticosteroids to manage adverse effects such as cytokine release syndrome (CRS) does not significantly impact the therapeutic outcomes of CAR T-cell therapy. Nonetheless, it is prudent to use corticosteroids with caution.<xref ref-type="bibr" rid="article-36238.r66">[66]</xref></p>
        <p><bold>Hepatic enzyme inducers</bold>: Co-administration with enzyme inducers such as phenobarbital, phenytoin, and rifampin may increase the metabolic clearance of methylprednisolone, necessitating potential dose adjustments to maintain therapeutic efficacy.</p>
        <p><bold>Hepatic enzyme inhibitors</bold>: Co-administration with enzyme inhibitors like ketoconazole/itraconazole may reduce the clearance of methylprednisolone, potentially increasing the risk of toxicity; dose titration may be required.<xref ref-type="bibr" rid="article-36238.r67">[67]</xref></p>
        <p><bold>Oral anticoagulants</bold>: The effect of methylprednisolone on oral anticoagulants can be variable, with reported cases of both enhanced and diminished anticoagulant activity. Regular monitoring of coagulation parameters is essential to ensure the desired anticoagulant effect is achieved.<xref ref-type="bibr" rid="article-36238.r68">[68]</xref><xref ref-type="bibr" rid="article-36238.r69">[69]</xref></p>
        <p><bold>Live vaccines:</bold>&#x000a0;The Advisory Committee on Immunization Practices (ACIP) recommends that live-virus vaccines should be avoided during and shortly after high-dose corticosteroid therapy (&#x02265;2 mg/kg or &#x02265;20 mg/day of prednisone for &#x02265;14 days) due to potential immunosuppression. Live virus vaccination is generally deferred for at least&#x000a0;1 month after discontinuing.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.html">[80]</ext-link></p>
      </sec>
      <sec id="article-36238.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Contraindications to methylprednisolone administration include documented hypersensitivity to the drug or components, systemic fungal infection, intrathecal administration, live or attenuated virus vaccine, and idiopathic thrombocytopenic purpura.<xref ref-type="bibr" rid="article-36238.r70">[70]</xref>&#x000a0;Like all other glucocorticoids, methylprednisolone must be used with great caution in patients with peptic ulcers, heart disease or hypertension with heart failure, certain infectious illnesses such as varicella and tuberculosis psychoses, diabetes, osteoporosis, or glaucoma.<xref ref-type="bibr" rid="article-36238.r71">[71]</xref></p>
        <p>
<bold>Warning and Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Certain formulations of methylprednisolone contain benzyl alcohol, which is known to cause gasping syndrome in infants; these formulations should be avoided in premature infants. The label should be consulted for excipients before use.</p>
          </list-item>
          <list-item>
            <p>Certain formulations of methylprednisolone contain lactose, which is contraindicated in individuals with hypersensitivity to dairy products.<xref ref-type="bibr" rid="article-36238.r72">[72]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-36238.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Blood pressure, blood glucose, electrolytes, weight, bone mineral density, hypothalamic-pituitary-adrenal axis suppression, and intraocular pressure all require monitoring in patients taking methylprednisolone. Growth and development monitoring should be in place for children. Patients receiving methylprednisolone must be monitored carefully for the development of hyperglycemia, glycosuria, sodium retention with edema or hypertension, hypokalemia, peptic ulcers, and osteoporosis. Corticosteroid use raises the risk of reactivation of latent tuberculosis infection (LTBI).<xref ref-type="bibr" rid="article-36238.r73">[73]</xref><xref ref-type="bibr" rid="article-36238.r74">[74]</xref>&#x000a0;The dosage should be as low as possible. Even patients maintained on low doses of methylprednisolone may require supplementary therapy&#x000a0;during times of stress, such as during surgery, intercurrent illness, or trauma.<xref ref-type="bibr" rid="article-36238.r75">[75]</xref></p>
      </sec>
      <sec id="article-36238.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Most of the toxic effects of methylprednisolone and other glucocorticoids are predictable from their impact on the body's physiology. Some are life-threatening and include metabolic effects (eg, growth inhibition, diabetes, muscle wasting, osteoporosis), salt retention (although less common with methylprednisolone), and psychosis.<xref ref-type="bibr" rid="article-36238.r76">[76]</xref></p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Treatment of acute overdose involves supportive and symptomatic care. Methods for minimizing these toxicities include local application, alternate-day therapy (to reduce pituitary suppression), and tapering the dose promptly after attaining a therapeutic response.<xref ref-type="bibr" rid="article-36238.r77">[77]</xref> Additional "stress doses" may be necessary during severe illness or before major surgery to prevent adrenal insufficiency in patients who have received long-term treatment with methylprednisolone. Treatment of acute overdose involves supportive and symptomatic care.</p>
      </sec>
      <sec id="article-36238.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Methylprednisolone is widely used in multiple fields due to its anti-inflammatory and immunosuppressive properties. Interprofessional healthcare team members, including nurses, pharmacists, advanced practice&#x000a0;providers, and physicians, should be aware of its broad spectrum of clinical applications, both labeled and off-label indications, while considering its contraindications and individualizing its use based on the patient's comorbidities and tolerance of side effects. Of particular importance, patients receiving methylprednisolone should undergo monitoring for the development of hyperglycemia, hypertension, peptic ulcer, osteoporosis, and hidden infections. The healthcare team should&#x000a0;monitor for adverse effects in inpatient and outpatient settings. Pharmacists should be involved in verifying dosing and performing medication reconciliation. Both pharmacists and nurses need to alert other members of the&#x000a0;healthcare team if they encounter any issues of concern. All these interprofessional healthcare team members must communicate and collaborate across interprofessional lines to ensure optimal therapeutic results.</p>
        <p>As with all glucocorticoids, methylprednisolone's adverse effects are both dose- and duration-dependent and can range from nonserious displeasing appearances to those that are life-threatening. Interprofessional coordination and care between healthcare professionals are needed to ensure that methylprednisolone dosage remains minimal and that the treatment goals are achieved in the shortest period. Preexisting comorbidities that may become exacerbated when treated with methylprednisolone require management, and patients under treatment should be monitored by the pharmacist, nurse, and clinician for adverse effects, identifying who may benefit from additional intervention. An interprofessional team approach leads to the best outcomes.&#x000a0;An interprofessional team approach and communication among clinicians, pharmacists, specialists, and nurses are crucial to decreasing potential adverse effects, improving disease course and quality of life, and improving patient outcomes&#x000a0;related&#x000a0;to methylprednisolone therapy.</p>
      </sec>
      <sec id="article-36238.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=36238&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=36238">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/36238/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=36238">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-36238.s11">
        <title>References</title>
        <ref id="article-36238.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torrelo</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Methylprednisolone aceponate for atopic dermatitis.</article-title>
            <source>Int J Dermatol</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>56</volume>
            <issue>6</issue>
            <fpage>691</fpage>
            <page-range>691-697</page-range>
            <pub-id pub-id-type="pmid">28258632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lachapelle</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Gimenez-Arnau</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Metz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Proksch</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Best practices, new perspectives and the perfect emollient: optimizing the management of contact dermatitis.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2018</year>
            <month>May</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>241</fpage>
            <page-range>241-251</page-range>
            <pub-id pub-id-type="pmid">28866951</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rose</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wever</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zilliken</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Linse</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Haustein</surname>
                <given-names>UF</given-names>
              </name>
              <name>
                <surname>Br&#x000f6;cker</surname>
                <given-names>EB</given-names>
              </name>
            </person-group>
            <article-title>Intravenous dexamethasone-cyclophosphamide pulse therapy in comparison with oral methylprednisolone-azathioprine therapy in patients with pemphigus: results of a multicenter prospectively randomized study.</article-title>
            <source>J Dtsch Dermatol Ges</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>200</fpage>
            <page-range>200-6</page-range>
            <pub-id pub-id-type="pmid">16372814</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Del Pozzo-Magana</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Lazo-Langner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carleton</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Castro-Pastrana</surname>
                <given-names>LI</given-names>
              </name>
              <name>
                <surname>Rieder</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>A systematic review of treatment of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children.</article-title>
            <source>J Popul Ther Clin Pharmacol</source>
            <year>2011</year>
            <volume>18</volume>
            <fpage>e121</fpage>
            <page-range>e121-33</page-range>
            <pub-id pub-id-type="pmid">21467603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Speiser</surname>
                <given-names>PW</given-names>
              </name>
              <name>
                <surname>Arlt</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Auchus</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Baskin</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Conway</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Merke</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Meyer-Bahlburg</surname>
                <given-names>HFL</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Murad</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Oberfield</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>PC</given-names>
              </name>
            </person-group>
            <article-title>Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2018</year>
            <month>Nov</month>
            <day>01</day>
            <volume>103</volume>
            <issue>11</issue>
            <fpage>4043</fpage>
            <page-range>4043-4088</page-range>
            <pub-id pub-id-type="pmid">30272171</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Unal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Durmaz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Erko&#x000e7;o&#x0011f;lu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bayrak&#x000e7;i</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bircan</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Alika&#x0015f;ifo&#x0011f;lu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cetin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The rapid correction of hypercalcemia at presentation of acute lymphoblastic leukemia using high-dose methylprednisolone.</article-title>
            <source>Turk J Pediatr</source>
            <year>2008</year>
            <season>Mar-Apr</season>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>171</fpage>
            <page-range>171-5</page-range>
            <pub-id pub-id-type="pmid">18664083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenberg</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ireland</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jewell</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>High-dose methylprednisolone in the treatment of active ulcerative colitis.</article-title>
            <source>J Clin Gastroenterol</source>
            <year>1990</year>
            <month>Feb</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>40</fpage>
            <page-range>40-1</page-range>
            <pub-id pub-id-type="pmid">2303687</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jaime-P&#x000e9;rez</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Rodr&#x000ed;guez-Mart&#x000ed;nez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-de-Le&#x000f3;n</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tar&#x000ed;n-Arzaga</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-Almaguer</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Current approaches for the treatment of autoimmune hemolytic anemia.</article-title>
            <source>Arch Immunol Ther Exp (Warsz)</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>61</volume>
            <issue>5</issue>
            <fpage>385</fpage>
            <page-range>385-95</page-range>
            <pub-id pub-id-type="pmid">23689532</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frickhofen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kaltwasser</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Schrezenmeier</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Raghavachar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vogt</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Herrmann</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Freund</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meusers</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Salama</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heimpel</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group.</article-title>
            <source>N Engl J Med</source>
            <year>1991</year>
            <month>May</month>
            <day>09</day>
            <volume>324</volume>
            <issue>19</issue>
            <fpage>1297</fpage>
            <page-range>1297-304</page-range>
            <pub-id pub-id-type="pmid">2017225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Godeau</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chevret</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Varet</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lefr&#x000e8;re</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zini</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Bassompierre</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ch&#x000e8;ze</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Legouffe</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hulin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grange</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Fain</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bierling</surname>
                <given-names>P</given-names>
              </name>
              <collab>French ATIP Study Group</collab>
            </person-group>
            <article-title>Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial.</article-title>
            <source>Lancet</source>
            <year>2002</year>
            <month>Jan</month>
            <day>05</day>
            <volume>359</volume>
            <issue>9300</issue>
            <fpage>23</fpage>
            <page-range>23-9</page-range>
            <pub-id pub-id-type="pmid">11809183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murray</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of multiple sclerosis.</article-title>
            <source>BMJ</source>
            <year>2006</year>
            <month>Mar</month>
            <day>04</day>
            <volume>332</volume>
            <issue>7540</issue>
            <fpage>525</fpage>
            <page-range>525-7</page-range>
            <pub-id pub-id-type="pmid">16513709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Charkoudian</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Ying</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Pujari</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Gangaputra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thorne</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Jabs</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Levy-Clarke</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Nussenblatt</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Rosenbaum</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Suhler</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Kempen</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>High-dose intravenous corticosteroids for ocular inflammatory diseases.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2012</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>91</fpage>
            <page-range>91-9</page-range>
            <pub-id pub-id-type="pmid">22409561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murnaghan</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Vasmant</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bensman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pulse methylprednisolone therapy in severe idiopathic childhood nephrotic syndrome.</article-title>
            <source>Acta Paediatr Scand</source>
            <year>1984</year>
            <month>Nov</month>
            <volume>73</volume>
            <issue>6</issue>
            <fpage>733</fpage>
            <page-range>733-9</page-range>
            <pub-id pub-id-type="pmid">6524363</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Illei</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Austin</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Crane</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gourley</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Yarboro</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Vaughan</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Kuroiwa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Danning</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Klippel</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Balow</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Boumpas</surname>
                <given-names>DT</given-names>
              </name>
            </person-group>
            <article-title>Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.</article-title>
            <source>Ann Intern Med</source>
            <year>2001</year>
            <month>Aug</month>
            <day>21</day>
            <volume>135</volume>
            <issue>4</issue>
            <fpage>248</fpage>
            <page-range>248-57</page-range>
            <pub-id pub-id-type="pmid">11511139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Corticosteroids in treatment of aspiration-related acute respiratory distress syndrome: results of a retrospective cohort study.</article-title>
            <source>BMC Pulm Med</source>
            <year>2016</year>
            <month>Feb</month>
            <day>10</day>
            <volume>16</volume>
            <fpage>29</fpage>
            <pub-id pub-id-type="pmid">26864571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alangari</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Corticosteroids in the treatment of acute asthma.</article-title>
            <source>Ann Thorac Med</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>187</fpage>
            <page-range>187-92</page-range>
            <pub-id pub-id-type="pmid">25276236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rhee</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Min</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Yim</surname>
                <given-names>NY</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Jeon</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia.</article-title>
            <source>Eur Respir J</source>
            <year>2013</year>
            <month>Feb</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>402</fpage>
            <page-range>402-9</page-range>
            <pub-id pub-id-type="pmid">22599359</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wallaert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ramon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Fournier</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Hatron</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Muir</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Tonnel</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Voisin</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>High-dose methylprednisolone pulse therapy in sarcoidosis.</article-title>
            <source>Eur J Respir Dis</source>
            <year>1986</year>
            <month>Apr</month>
            <volume>68</volume>
            <issue>4</issue>
            <fpage>256</fpage>
            <page-range>256-62</page-range>
            <pub-id pub-id-type="pmid">3732422</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herdy</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Pinto</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Olivaes</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Carvalho</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Tchou</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cosendey</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ribeiro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Azeredo</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>de Souza</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Herdy</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>VG</given-names>
              </name>
            </person-group>
            <article-title>Rheumatic carditis treated with high doses of pulsetherapy methylprednisolone. Results in 70 children over 12 years.</article-title>
            <source>Arq Bras Cardiol</source>
            <year>1999</year>
            <month>May</month>
            <volume>72</volume>
            <issue>5</issue>
            <fpage>601</fpage>
            <page-range>601-6</page-range>
            <pub-id pub-id-type="pmid">10668230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Groff</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Franck</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Raddatz</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Systemic steroid therapy for acute gout: a clinical trial and review of the literature.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>1990</year>
            <month>Jun</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>329</fpage>
            <page-range>329-36</page-range>
            <pub-id pub-id-type="pmid">2196674</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peters</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Ejstrup</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Intravenous methylprednisolone pulse therapy in ankylosing spondylitis.</article-title>
            <source>Scand J Rheumatol</source>
            <year>1992</year>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>134</fpage>
            <page-range>134-8</page-range>
            <pub-id pub-id-type="pmid">1604251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsubara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hirai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sawa</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Pulsed intravenous methylprednisolone therapy for inflammatory myopathies: evaluation of the effect by comparing two consecutive biopsies from the same muscle.</article-title>
            <source>J Neuroimmunol</source>
            <year>1997</year>
            <month>Jun</month>
            <volume>76</volume>
            <issue>1-2</issue>
            <fpage>75</fpage>
            <page-range>75-80</page-range>
            <pub-id pub-id-type="pmid">9184635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nash</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Therapies for axial disease in psoriatic arthritis. A systematic review.</article-title>
            <source>J Rheumatol</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>33</volume>
            <issue>7</issue>
            <fpage>1431</fpage>
            <page-range>1431-4</page-range>
            <pub-id pub-id-type="pmid">16724371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Ahern</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Roberts-Thomson</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Pulse methylprednisolone therapy in rheumatoid arthritis: unproved therapy, unjustified therapy, or effective adjunctive treatment?</article-title>
            <source>Ann Rheum Dis</source>
            <year>1990</year>
            <month>Apr</month>
            <volume>49</volume>
            <issue>4</issue>
            <fpage>265</fpage>
            <page-range>265-7</page-range>
            <pub-id pub-id-type="pmid">2187419</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Badsha</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Intravenous pulses of methylprednisolone for systemic lupus erythematosus.</article-title>
            <source>Semin Arthritis Rheum</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>32</volume>
            <issue>6</issue>
            <fpage>370</fpage>
            <page-range>370-7</page-range>
            <pub-id pub-id-type="pmid">12833245</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pyne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ioannou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mootoo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bhanji</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Intra-articular steroids in knee osteoarthritis: a comparative study of triamcinolone hexacetonide and methylprednisolone acetate.</article-title>
            <source>Clin Rheumatol</source>
            <year>2004</year>
            <month>Apr</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>116</fpage>
            <page-range>116-20</page-range>
            <pub-id pub-id-type="pmid">15045624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garg</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Perry</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Deodhar</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Intra-articular and soft tissue injections, a systematic review of relative efficacy of various corticosteroids.</article-title>
            <source>Clin Rheumatol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>33</volume>
            <issue>12</issue>
            <fpage>1695</fpage>
            <page-range>1695-706</page-range>
            <pub-id pub-id-type="pmid">24651914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Senila</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Danescu</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Ungureanu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Candrea</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cosgarea</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Intravenous methylprednisolone pulse therapy in severe alopecia areata.</article-title>
            <source>Indian J Dermatol Venereol Leprol</source>
            <year>2015</year>
            <season>Jan-Feb</season>
            <volume>81</volume>
            <issue>1</issue>
            <fpage>95</fpage>
            <pub-id pub-id-type="pmid">25566921</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fabbri</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cardinali</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Giomi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Caproni</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Cutaneous lupus erythematosus: diagnosis and management.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2003</year>
            <volume>4</volume>
            <issue>7</issue>
            <fpage>449</fpage>
            <page-range>449-65</page-range>
            <pub-id pub-id-type="pmid">12814335</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Syed</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bayat</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Superior effect of combination vs. single steroid therapy in keloid disease: a comparative in vitro analysis of glucocorticoids.</article-title>
            <source>Wound Repair Regen</source>
            <year>2013</year>
            <season>Jan-Feb</season>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>88</fpage>
            <page-range>88-102</page-range>
            <pub-id pub-id-type="pmid">23126666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Snyder</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Elias</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Intermittent megadose corticosteroid therapy for generalized lichen planus.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1982</year>
            <month>Jun</month>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>1089</fpage>
            <page-range>1089-90</page-range>
            <pub-id pub-id-type="pmid">7096672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fehlings</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Tetreault</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Aarabi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Brodke</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Chiba</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dettori</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Furlan</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Hawryluk</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Holly</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Howley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jeji</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kalsi-Ryan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kotter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kurpad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>BK</given-names>
              </name>
              <name>
                <surname>Marino</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Massicotte</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Merli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Middleton</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Nakashima</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nagoshi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Palmieri</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Skelly</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Vaccaro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Harrop</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>A Clinical Practice Guideline for the Management of Patients With Acute Spinal Cord Injury: Recommendations on the Use of Methylprednisolone Sodium Succinate.</article-title>
            <source>Global Spine J</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>7</volume>
            <issue>3 Suppl</issue>
            <fpage>203S</fpage>
            <page-range>203S-211S</page-range>
            <pub-id pub-id-type="pmid">29164025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>LJW</given-names>
              </name>
              <name>
                <surname>Rosner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cragg</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Journal Club: High-dose methylprednisolone for acute traumatic spinal cord injury: A meta-analysis.</article-title>
            <source>Neurology</source>
            <year>2020</year>
            <month>Aug</month>
            <day>11</day>
            <volume>95</volume>
            <issue>6</issue>
            <fpage>272</fpage>
            <page-range>272-274</page-range>
            <pub-id pub-id-type="pmid">32269114</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ozawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Uzawa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kanai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Oda</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Yasuda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kawaguchi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Himuro</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kuwabara</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis.</article-title>
            <source>J Neurol Sci</source>
            <year>2019</year>
            <month>Jul</month>
            <day>15</day>
            <volume>402</volume>
            <fpage>12</fpage>
            <page-range>12-15</page-range>
            <pub-id pub-id-type="pmid">31100651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ologundudu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brignardello-Petersen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Guyatt</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Oykhman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Saini</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Waserman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moellman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Ben-Shoshan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Oliver</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mathur</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Winders</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Eftekhari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gardner</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Runyon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Asiniwasis</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wheeler</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Trayes</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Systemic Corticosteroids for Urticaria: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2024</year>
            <month>Jul</month>
            <volume>12</volume>
            <issue>7</issue>
            <fpage>1879</fpage>
            <page-range>1879-1889.e8</page-range>
            <pub-id pub-id-type="pmid">38642709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>YF</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>XY</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>You</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of iguratimod combined with methylprednisolone for primary Sj&#x000f6;gren's syndrome: a meta-analysis and trial sequential analysis.</article-title>
            <source>Eur Rev Med Pharmacol Sci</source>
            <year>2023</year>
            <month>Aug</month>
            <volume>27</volume>
            <issue>16</issue>
            <fpage>7544</fpage>
            <page-range>7544-7556</page-range>
            <pub-id pub-id-type="pmid">37667931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <collab>Committee on Practice Bulletins-Obstetrics</collab>
            <article-title>ACOG Practice Bulletin No. 189: Nausea And Vomiting Of Pregnancy.</article-title>
            <source>Obstet Gynecol</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>131</volume>
            <issue>1</issue>
            <fpage>e15</fpage>
            <page-range>e15-e30</page-range>
            <pub-id pub-id-type="pmid">29266076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Qiao</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>A systematic review and meta-analysis of glucocorticoids treatment in severe COVID-19: methylprednisolone versus dexamethasone.</article-title>
            <source>BMC Infect Dis</source>
            <year>2023</year>
            <month>May</month>
            <day>05</day>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>290</fpage>
            <pub-id pub-id-type="pmid">37147596</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewandowski</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Kawalec</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kusi&#x00144;ski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>D&#x00105;browska</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Matusiak</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Dudek</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lewi&#x00144;ski</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>The Utility of Intravenous Methylprednisolone as an Adjunct Treatment for Drug-Resistant Amiodarone-Induced Thyrotoxicosis.</article-title>
            <source>J Clin Med</source>
            <year>2024</year>
            <month>Jan</month>
            <day>06</day>
            <volume>13</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">38256458</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Langhoff</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ladefoged</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Relative immunosuppressive potency of various corticosteroids measured in vitro.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>1983</year>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>459</fpage>
            <page-range>459-62</page-range>
            <pub-id pub-id-type="pmid">6653640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Duff</surname>
                <given-names>GW</given-names>
              </name>
            </person-group>
            <article-title>A negative regulatory region containing a glucocorticosteroid response element (nGRE) in the human interleukin-1beta gene.</article-title>
            <source>DNA Cell Biol</source>
            <year>1997</year>
            <month>Feb</month>
            <volume>16</volume>
            <issue>2</issue>
            <fpage>145</fpage>
            <page-range>145-52</page-range>
            <pub-id pub-id-type="pmid">9052735</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scheinman</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Cogswell</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Lofquist</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Baldwin</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids.</article-title>
            <source>Science</source>
            <year>1995</year>
            <month>Oct</month>
            <day>13</day>
            <volume>270</volume>
            <issue>5234</issue>
            <fpage>283</fpage>
            <page-range>283-6</page-range>
            <pub-id pub-id-type="pmid">7569975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Auphan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>DiDonato</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Rosette</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Helmberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Karin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis.</article-title>
            <source>Science</source>
            <year>1995</year>
            <month>Oct</month>
            <day>13</day>
            <volume>270</volume>
            <issue>5234</issue>
            <fpage>286</fpage>
            <page-range>286-90</page-range>
            <pub-id pub-id-type="pmid">7569976</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>KT</given-names>
              </name>
            </person-group>
            <article-title>TNF-alpha-induced cyclooxygenase-2 expression in human lung epithelial cells: involvement of the phospholipase C-gamma 2, protein kinase C-alpha, tyrosine kinase, NF-kappa B-inducing kinase, and I-kappa B kinase 1/2 pathway.</article-title>
            <source>J Immunol</source>
            <year>2000</year>
            <month>Sep</month>
            <day>01</day>
            <volume>165</volume>
            <issue>5</issue>
            <fpage>2719</fpage>
            <page-range>2719-28</page-range>
            <pub-id pub-id-type="pmid">10946303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mathian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jouenne</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chader</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cohen-Aubart</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Haroche</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fadlallah</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cla&#x000eb;r</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Musset</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Gorochov</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Amoura</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Miyara</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Regulatory T Cell Responses to High-Dose Methylprednisolone in Active Systemic Lupus Erythematosus.</article-title>
            <source>PLoS One</source>
            <year>2015</year>
            <volume>10</volume>
            <issue>12</issue>
            <fpage>e0143689</fpage>
            <pub-id pub-id-type="pmid">26629828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shaw</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Issekutz</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Issekutz</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Gluconeogenesis from glycerol at rest and during exercise in normal, diabetic, and methylprednisolone-treated dogs.</article-title>
            <source>Metabolism</source>
            <year>1976</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>329</fpage>
            <page-range>329-39</page-range>
            <pub-id pub-id-type="pmid">1250166</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Upadhyay</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Dubey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ahi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Beotra</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bhardwaj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shukla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A preliminary study on urinary excretion patterns of methylprednisolone after oral and intra-articular administration and effect on endogenous glucocorticosteroids profile.</article-title>
            <source>Indian J Pharmacol</source>
            <year>2021</year>
            <season>Nov-Dec</season>
            <volume>53</volume>
            <issue>6</issue>
            <fpage>480</fpage>
            <page-range>480-483</page-range>
            <pub-id pub-id-type="pmid">34975136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Czock</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rasche</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>H&#x000e4;ussler</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2005</year>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <page-range>61-98</page-range>
            <pub-id pub-id-type="pmid">15634032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Garg</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Weidler</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Sakmar</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Preliminary in vitro and in vivo investigations on methylprednisolone and its acetate.</article-title>
            <source>Res Commun Chem Pathol Pharmacol</source>
            <year>1978</year>
            <month>Oct</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-48</page-range>
            <pub-id pub-id-type="pmid">725320</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ditzian-Kadanoff</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ellman</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>How safe is it? High dose intravenous methylprednisolone.</article-title>
            <source>IMJ Ill Med J</source>
            <year>1987</year>
            <month>Dec</month>
            <volume>172</volume>
            <issue>6</issue>
            <fpage>432</fpage>
            <page-range>432-4</page-range>
            <pub-id pub-id-type="pmid">2892818</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moromizato</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sakaniwa</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tokuda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Taniguchi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shibuya</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Intravenous methylprednisolone pulse therapy and the risk of in-hospital mortality among acute COVID-19 patients: Nationwide clinical cohort study.</article-title>
            <source>Crit Care</source>
            <year>2023</year>
            <month>Feb</month>
            <day>08</day>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <pub-id pub-id-type="pmid">36755340</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campbell</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Nicklas</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Sadosty</surname>
                <given-names>AT</given-names>
              </name>
              <collab>Members of the Joint Task Force</collab>
              <collab>Practice Parameter Workgroup</collab>
            </person-group>
            <article-title>Emergency department diagnosis and treatment of anaphylaxis: a practice parameter.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2014</year>
            <month>Dec</month>
            <volume>113</volume>
            <issue>6</issue>
            <fpage>599</fpage>
            <page-range>599-608</page-range>
            <pub-id pub-id-type="pmid">25466802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubin</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Ananthakrishnan</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Sauer</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>ACG Clinical Guideline: Ulcerative Colitis in Adults.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>114</volume>
            <issue>3</issue>
            <fpage>384</fpage>
            <page-range>384-413</page-range>
            <pub-id pub-id-type="pmid">30840605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <collab>Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group</collab>
            <article-title>KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS.</article-title>
            <source>Kidney Int</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>105</volume>
            <issue>1S</issue>
            <fpage>S1</fpage>
            <page-range>S1-S69</page-range>
            <pub-id pub-id-type="pmid">38182286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>DZ</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>FC</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of corticosteroid therapy in patients with cardiac arrest: A meta-analysis of randomized controlled trials.</article-title>
            <source>Am J Emerg Med</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>75</volume>
            <fpage>111</fpage>
            <page-range>111-118</page-range>
            <pub-id pub-id-type="pmid">37939521</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Onel</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Horton</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Lovell</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Shenoi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cuello</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Angeles-Han</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Cron</surname>
                <given-names>RQ</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Ferguson</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Gewanter</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Guzman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nigrovic</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Ombrello</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Rabinovich</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Tesher</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Twilt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Klein-Gitelman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barbar-Smiley</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Edelheit</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gillispie-Taylor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hays</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mannion</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Flanagan</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Saad</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Szymanski</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Trachtman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Turgunbaev</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Veiga</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Reston</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>74</volume>
            <issue>4</issue>
            <fpage>553</fpage>
            <page-range>553-569</page-range>
            <pub-id pub-id-type="pmid">35233993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trautmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vivarelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Samuel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gipson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sinha</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schaefer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hui</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Saleem</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Feltran</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller-Deile</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Becker</surname>
                <given-names>JU</given-names>
              </name>
              <name>
                <surname>Cano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>YN</given-names>
              </name>
              <name>
                <surname>Smoyer</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Anochie</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nakanishi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hodson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Haffner</surname>
                <given-names>D</given-names>
              </name>
              <collab>International Pediatric Nephrology Association</collab>
            </person-group>
            <article-title>IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome.</article-title>
            <source>Pediatr Nephrol</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>35</volume>
            <issue>8</issue>
            <fpage>1529</fpage>
            <page-range>1529-1561</page-range>
            <pub-id pub-id-type="pmid">32382828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blagojevic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Legendre</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Matucci-Cerinic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mouthon</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Is there today a place for corticosteroids in the treatment of scleroderma?</article-title>
            <source>Autoimmun Rev</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>12</issue>
            <fpage>102403</fpage>
            <pub-id pub-id-type="pmid">31639515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <article-title>ACOG Committee Opinion No. 776: Immune Modulating Therapies in Pregnancy and Lactation.</article-title>
            <source>Obstet Gynecol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>133</volume>
            <issue>4</issue>
            <fpage>e287</fpage>
            <page-range>e287-e295</page-range>
            <pub-id pub-id-type="pmid">30913201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r60">
          <label>60</label>
          <element-citation publication-type="book">
            <chapter-title>Methylprednisolone</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>4</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Abril</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Langford</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Gorelik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Guyatt</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Archer</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Conn</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Full</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Grayson</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Ibarra</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Imundo</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stone</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Sule</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sundel</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Vitobaldi</surname>
                <given-names>OI</given-names>
              </name>
              <name>
                <surname>Warner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Byram</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Dua</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Husainat</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Kalot</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Springer</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Turgunbaev</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Villa-Forte</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Mustafa</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis.</article-title>
            <source>Arthritis Rheumatol</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>73</volume>
            <issue>8</issue>
            <fpage>1349</fpage>
            <page-range>1349-1365</page-range>
            <pub-id pub-id-type="pmid">34235884</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stanbury</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>Systemic corticosteroid therapy--side effects and their management.</article-title>
            <source>Br J Ophthalmol</source>
            <year>1998</year>
            <month>Jun</month>
            <volume>82</volume>
            <issue>6</issue>
            <fpage>704</fpage>
            <page-range>704-8</page-range>
            <pub-id pub-id-type="pmid">9797677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Jabr</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Alhumaidan</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Alghamdi</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Almutairi</surname>
                <given-names>MSL</given-names>
              </name>
              <name>
                <surname>Alsubaihi</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Alrasheedi</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Alkhdairi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Alzweihary</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Alrasheedi</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Alrasheedi</surname>
                <given-names>KAM</given-names>
              </name>
              <name>
                <surname>Alrashdi</surname>
                <given-names>MN</given-names>
              </name>
            </person-group>
            <article-title>Awareness of Side Effects of Corticosteroids among Users and Nonusers in Saudi Arabia.</article-title>
            <source>J Pharm Bioallied Sci</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>16</volume>
            <issue>Suppl 2</issue>
            <fpage>S1612</fpage>
            <page-range>S1612-S1618</page-range>
            <pub-id pub-id-type="pmid">38882861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torpy</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Lim</surname>
                <given-names>WT</given-names>
              </name>
            </person-group>
            <article-title>Glucocorticoid-induced adrenal suppression: physiological basis and strategies for glucocorticoid weaning.</article-title>
            <source>Med J Aust</source>
            <year>2023</year>
            <month>Nov</month>
            <day>20</day>
            <volume>219</volume>
            <issue>10</issue>
            <fpage>444</fpage>
            <page-range>444-447</page-range>
            <pub-id pub-id-type="pmid">37884339</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hampe</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Daumoine</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Limagne</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Roussot</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Borsotti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ilie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Truntzer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ghiringhelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Thibaudin</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Effect of radiochemotherapy on peripheral immune response in glioblastoma.</article-title>
            <source>Cancer Immunol Immunother</source>
            <year>2024</year>
            <month>May</month>
            <day>16</day>
            <volume>73</volume>
            <issue>7</issue>
            <fpage>133</fpage>
            <pub-id pub-id-type="pmid">38753169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lakomy</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Akhoundova</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nilius</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kronig</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Novak</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Daskalakis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bacher</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Pabst</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome.</article-title>
            <source>Biomolecules</source>
            <year>2023</year>
            <month>Feb</month>
            <day>17</day>
            <volume>13</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">36830750</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lebrun-Vignes</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Archer</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Diquet</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Levron</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Chosidow</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Puech</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Warot</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2001</year>
            <month>May</month>
            <volume>51</volume>
            <issue>5</issue>
            <fpage>443</fpage>
            <page-range>443-50</page-range>
            <pub-id pub-id-type="pmid">11422002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peng</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>TW</given-names>
              </name>
            </person-group>
            <article-title>Interactions Between Warfarin and Prednisolone: A Case Report.</article-title>
            <source>Am J Ther</source>
            <year>2017</year>
            <season>Jul/Aug</season>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>e494</fpage>
            <pub-id pub-id-type="pmid">27849633</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hazlewood</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Fugate</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <article-title>Effect of oral corticosteroids on chronic warfarin therapy.</article-title>
            <source>Ann Pharmacother</source>
            <year>2006</year>
            <month>Dec</month>
            <volume>40</volume>
            <issue>12</issue>
            <fpage>2101</fpage>
            <page-range>2101-6</page-range>
            <pub-id pub-id-type="pmid">17119104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r70">
          <label>70</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferrell</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Anaphylactic Reaction to Methylprednisolone.</article-title>
            <source>J Emerg Nurs</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>41</volume>
            <issue>6</issue>
            <fpage>470</fpage>
            <page-range>470-3</page-range>
            <pub-id pub-id-type="pmid">26296715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r71">
          <label>71</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tseng</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>FY</given-names>
              </name>
            </person-group>
            <article-title>Short-term use of glucocorticoids and risk of peptic ulcer bleeding: a nationwide population-based case-crossover study.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>599</fpage>
            <page-range>599-606</page-range>
            <pub-id pub-id-type="pmid">26096497</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r72">
          <label>72</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Porcaro</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Paglietti</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Diamanti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Petreschi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schiavino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Negro</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Pecora</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fiocchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cutrera</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Anaphylactic shock with methylprednisolone sodium succinate in a child with short bowel syndrome and cow's milk allergy.</article-title>
            <source>Ital J Pediatr</source>
            <year>2017</year>
            <month>Nov</month>
            <day>17</day>
            <volume>43</volume>
            <issue>1</issue>
            <fpage>104</fpage>
            <pub-id pub-id-type="pmid">29149860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r73">
          <label>73</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jadhav</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Short Course of High-dose Steroids for Anaphylaxis Caused Flare Up of Tuberculosis: A Case Report.</article-title>
            <source>J Transl Int Med</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>39</fpage>
            <page-range>39-42</page-range>
            <pub-id pub-id-type="pmid">30997356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r74">
          <label>74</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fehily</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Al-Ani</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Abdelmalak</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rentch</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Denholm</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ng</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Rubin</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2022</year>
            <month>Jul</month>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-27</page-range>
            <pub-id pub-id-type="pmid">35596242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r75">
          <label>75</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pitre</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Drover</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chaudhuri</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zeraaktkar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Menon</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gershengorn</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Jayaprakash</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Spencer-Segal</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Pastores</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Nei</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Annane</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rochwerg</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Corticosteroids in Sepsis and Septic Shock: A Systematic Review, Pairwise, and Dose-Response Meta-Analysis.</article-title>
            <source>Crit Care Explor</source>
            <year>2024</year>
            <month>Jan</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>e1000</fpage>
            <pub-id pub-id-type="pmid">38250247</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r76">
          <label>76</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bachu</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Abdulrahim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Harbaugh</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kotapati</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Srinivas</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Corticosteroid-Induced Psychosis: A Report of Three Cases.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>May</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>e39221</fpage>
            <pub-id pub-id-type="pmid">37337486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-36238.r77">
          <label>77</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mandell</surname>
                <given-names>BF</given-names>
              </name>
            </person-group>
            <article-title>Balancing the myths of corticosteroid therapy.</article-title>
            <source>Cleve Clin J Med</source>
            <year>2022</year>
            <month>Sep</month>
            <day>01</day>
            <volume>89</volume>
            <issue>9</issue>
            <fpage>480</fpage>
            <page-range>480-481</page-range>
            <pub-id pub-id-type="pmid">37907445</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
